Primary Immunodeficiency Diseases clinical trials at UC Irvine

1 research study open to eligible people

Showing trials for

  • About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

    open to eligible people ages 2 years and up

    The main aim of this study is to evaluate the PK, safety, tolerability and immunogenicity of subcutaneous (SC) administration of TAK-881 in adult and pediatric participants with PIDD and compare them to HYQVIA in participants 16 years old and older. The participants will be treated with TAK-881/HYQVIA or HYQVIA/TAK-881 with the same dose and dosing interval of immunoglobulin for up to 51 weeks (for participants greater than or equal to [>=]16 years) and only with TAK-881 for up to 27 weeks (for participants aged 2 to less than [<]16 years) as they were treated with another immunoglobulin before enrollment. Participants will need to visit the clinic every 3 or 4 weeks during the duration of the study.

    Irvine, California and other locations

Our lead scientists for Primary Immunodeficiency Diseases research studies include .

Last updated: